Coccidiosis is a widespread disease caused by a single cell parasite that can be seen only with the help of a microscope. Every livestock species as well as wild animals can be infected by coccidiosis, which is particularly prevalent when animals or birds are grouped together in significant numbers. The disease results in lower egg production in chickens and is responsible for mortality in the flock. Commonly, three to four species of coccidian are responsible for the outbreak of the disease. The severity of the disease depends on the number of oocyte ingested and on the species of coccidia. Anticoccidial drugs are those entities that combat the progression of coccidiosis in animals or birds. Anticoccidials are administered in the feed to prevent disease and minimize the economic loss often associated with sub-acute infections. Prophylactic use of anticoccidial drugs is preferred many a times as most of the damage occurs before clinical signs become apparent.
The anticoccidial drugs market can be segmented based on action, drug entity, and region. In terms of action, the anticoccidial drugs market can be classified into coccidiostatic and coccidiocidal. Based on drug entity, the anticoccidial drugs market can be categorized into ionophores and synthetic anticoccidials. The ionophores segment can be further divided into monovalent, monovalent glycoside, and divalent. Ionophores are the fermentation products of fungi species. They are extensively used as anticoccidial agents. Salinomycin, lasalocid, and monensin are the most commonly used ionophores. In terms of geography, the anticoccidial drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America accounts for a significant anticoccidial drugs market share in terms of revenue, due to a well-established infrastructure in immunological research, highly organized farming, increased demand for animal protein, high pet ownership, greater emphasis on prevention and wellness by veterinarians, and rise in spending on medicine. According to the USDA Economic Research Service, poultry is the fastest growing meat product in the organic products anticoccidial drugs market in the U.S.. The size of the poultry segment is around US$ 56 Mn. The segment expanded at an annual growth of 33% through 2008 (USDA, 2008). The high consumption of meat is expected to propel the anticoccidial drugs market in North America. Europe is a prominent region of the anticoccidial drugs market, owing to a highly developed health care industry, high government funding for the development of veterinary medicines, increased awareness among people, and high consumption of meat. The Biotechnology and Biological Sciences Research Council (BBSRC) donated GBP 5.7 Mn for the development of poultry vaccines to the London School of Hygiene and Tropical Medicine in December 2015.
The anticoccidial drugs market in Asia Pacific is expanding at a robust pace due to high rate of development in veterinary medicines and increase in government initiatives. Nowadays, major pharmaceutical companies are outsourcing their drug development services to various countries such as China, Singapore, Malaysia, and India, which is eventually propelling the growth of the anticoccidial drugs market in this region. The global anticoccidial drugs market is witnessing considerable growth owing to a rise in disposable income of people in emerging countries. Disposable income is increasing in emerging countries such as India and China, which results in a change in lifestyle and high demand for animal protein foods such as meat, milk, etc.. Increase in disposable income is likely to boost demand for veterinary pharmacies. Middle East and Latin America are expected to be the prospective regions of the anticoccidial drugs market in the near future due to rapidly developing pharmaceutical and biotechnology industries.
Some of the major players operating in the anticoccidial drugs market are Bayer Animal Heath, Boehringer Ingelheim, Ceva Santé Animale, Elanco, Novartis Animal Health, Merck Animal Health, Merial, Virbac S.A., and Zoetis.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.